High glucose changes extracellular adenosine triphosphate levels in rat retinal cultures.
Diabetic retinopathy (DR) is the leading cause of blindness in adults. In diabetes, there is activation of microglial cells and a concomitant release of inflammatory mediators. However, it remains unclear how diabetes triggers an inflammatory response in the retina. Activation of P2 purinergic receptors by adenosine triphosphate (ATP) may contribute to the inflammatory response in the retina, insofar as it has been shown to be associated with microglial activation and cytokine release. In this work, we evaluated how high glucose, used as a model of hyperglycemia, considered the main factor in the development of DR, affects the extracellular levels of ATP in retinal cell cultures. We found that basal extracellular ATP levels were not affected by high glucose or mannitol, but the extracellular elevation of ATP, after a depolarizing stimulus, was significantly higher in retinal cells cultured in high glucose compared with control or mannitol-treated cells. The increase in the extracellular ATP was prevented by application of botulinum neurotoxin A or by removal of extracellular calcium. In addition, degradation of exogenously added ATP was significantly lower in high-glucose-treated cells. It was also observed that, in retinal cells cultured under high-glucose conditions, the changes in the intracellular calcium concentrations were greater than those in control or mannitol-treated cells. In conclusion, in this work we have shown that high glucose alters the purinergic signaling system in the retina, by increasing the exocytotic release of ATP and decreasing its extracellular degradation. The resulting high levels of extracellular ATP may lead to inflammation involved in the pathogenesis of DR.
Costa
G
G
Center for Neuroscience and Cell Biology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
Pereira
T
T
Neto
A M
AM
Cristóvão
A J
AJ
Ambrósio
A F
AF
Santos
P F
PF
D000255:Adenosine Triphosphate / Q000378:metabolism*; D000704:Analysis of Variance; D000818:Animals; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage; D002118:Calcium / Q000378:metabolism; D002478:Cells, Cultured; D003930:Diabetic Retinopathy / Q000209:etiology; D004195:Disease Models, Animal; D005110:Extracellular Space / Q000378:metabolism; D005947:Glucose / Q000378:metabolism*; D006943:Hyperglycemia / Q000378:metabolism; D008353:Mannitol / Q000378:metabolism; D009498:Neurotoxins / Q000008:administration & dosage; D051381:Rats; D017208:Rats, Wistar; D012160:Retina / Q000378:metabolism*
D009498:Neurotoxins; D008353:Mannitol; D000255:Adenosine Triphosphate; D019274:Botulinum Toxins, Type A; D005947:Glucose; D002118:Calcium